Single-cell profiling reveals the importance of CXCL13/CXCR5 axis biology in lymphocyte-rich classic Hodgkin lymphoma

Biology in Practice: Harnessing the Curative Potential of the Immune System in Lymphoid Cancers

(2021) Tomohiro Aoki et al.   JOURNAL OF CLINICAL ONCOLOGY

CXCR5 CAR-T cells simultaneously target B cell non-Hodgkin’s lymphoma and tumor-supportive follicular T helper cells

(2021) Mario Bunse et al.   Nature Communications

Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium

(2020) Loretta J. Nastoupil et al.   JOURNAL OF CLINICAL ONCOLOGY

PD-L1 on dendritic cells attenuates T cell activation and regulates response to immune checkpoint blockade

(2020) Qi Peng et al.   Nature Communications

Programmed cell death protein1 (PD1)-expression in the microenvironment of classical Hodgkin lymphoma at relapse after conventional chemotherapy and at relapse on anti-PD1 treatment

(2019) Stephanie Sasse et al.   HAEMATOLOGICA

CXCL13 and Its Receptor CXCR5 in Cancer: Inflammation, Immune Response, and Beyond

(2019) Marcelo G. Kazanietz et al.   Frontiers in Endocrinology

Single-Cell Transcriptome Analysis Reveals Disease-Defining T-cell Subsets in the Tumor Microenvironment of Classic Hodgkin Lymphoma

(2019) Tomohiro Aoki et al.   Cancer Discovery

Mass cytometry of Hodgkin lymphoma reveals a CD4+exhausted T-effector and T-regulatory cell rich microenvironment

(2018) Fathima Zumla Cader et al.   BLOOD

Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma

(2018) Margaretha G.M. Roemer et al.   JOURNAL OF CLINICAL ONCOLOGY

Programmed cell death protein-1 (PD-1)-expression in the microenvironment of classical Hodgkin lymphoma at relapse during anti-PD-1-treatment

(2018) Stephanie Sasse et al.   HAEMATOLOGICA

Prognostic Model to Predict Post-Autologous Stem-Cell Transplantation Outcomes in Classical Hodgkin Lymphoma

(2017) Fong Chun Chan et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma

(2017) Robert Chen et al.   JOURNAL OF CLINICAL ONCOLOGY

The 2016 revision of the World Health Organization classification of lymphoid neoplasms

(2016) S. H. Swerdlow et al.   BLOOD

Loss of the HVEM Tumor Suppressor in Lymphoma and Restoration by Modified CAR-T Cells

(2016) Michael Boice et al.   CELL

Nivolumab in the Treatment of Hodgkin Lymphoma

(2016) Stephen M. Ansell   CLINICAL CANCER RESEARCH

PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome

(2016) Margaretha G.M. Roemer et al.   JOURNAL OF CLINICAL ONCOLOGY

Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial

(2016) Anas Younes et al.   LANCET ONCOLOGY

Classical Hodgkin Lymphoma with Reduced  2M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status

(2016) M. G. M. Roemer et al.   Cancer Immunology Research

Diffusion maps for high-dimensional single-cell analysis of differentiation data

(2015) Laleh Haghverdi et al.   BIOINFORMATICS

CXCL13 antibody for the treatment of autoimmune disorders

(2015) Ekaterina Klimatcheva et al.   BMC IMMUNOLOGY

Data-Driven Phenotypic Dissection of AML Reveals Progenitor-like Cells that Correlate with Prognosis

(2015) Jacob H. Levine et al.   CELL

TGF-β induces the differentiation of human CXCL13-producing CD4+ T cells

(2015) Shio Kobayashi et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

T Follicular Helper Cell Differentiation, Function, and Roles in Disease

(2014) Shane Crotty   IMMUNITY

Defining characteristics of classical Hodgkin lymphoma microenvironment T-helper cells

(2013) P. Greaves et al.   BLOOD

Constitutive AP-1 Activity and EBV Infection Induce PD-L1 in Hodgkin Lymphomas and Posttransplant Lymphoproliferative Disorders: Implications for Targeted Therapy

(2012) M. R. Green et al.   CLINICAL CANCER RESEARCH

Gene Expression–Based Model Using Formalin-Fixed Paraffin-Embedded Biopsies Predicts Overall Survival in Advanced-Stage Classical Hodgkin Lymphoma

(2012) David W. Scott et al.   JOURNAL OF CLINICAL ONCOLOGY

Expression of FOXP3, CD68, and CD20 at Diagnosis in the Microenvironment of Classical Hodgkin Lymphoma Is Predictive of Outcome

(2012) Paul Greaves et al.   JOURNAL OF CLINICAL ONCOLOGY

Densely Interconnected Transcriptional Circuits Control Cell States in Human Hematopoiesis

(2011) Noa Novershtern et al.   CELL

Molecular Pathogenesis of Hodgkin's Lymphoma: Increasing Evidence of the Importance of the Microenvironment

(2011) Christian Steidl et al.   JOURNAL OF CLINICAL ONCOLOGY

MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers

(2011) Christian Steidl et al.   NATURE

Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma

(2010) M. R. Green et al.   BLOOD

Tumor-Associated Macrophages and Survival in Classic Hodgkin's Lymphoma

(2010) Christian Steidl et al.   NEW ENGLAND JOURNAL OF MEDICINE

Lymphocyte-rich classical Hodgkin's lymphoma: distinctive tumor and microenvironment markers

(2009) Syong H Nam-Cha et al.   MODERN PATHOLOGY